CAS 54350-48-0 manufacturers and suppliers on PharmaCompass

PharmaCompass

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 54350-48-0, Tegison, Ethyl etrinoate, Retinoid, Etretinato, Ro 10-9359
Molecular Formula
C23H30O3
Molecular Weight
354.5  g/mol
InChI Key
HQMNCQVAMBCHCO-DJRRULDNSA-N
FDA UNII
65M2UDR9AG

CAS 54350-48-0
An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic.
1 2D Structure

CAS 54350-48-0

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
2.1.2 InChI
InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
2.1.3 InChI Key
HQMNCQVAMBCHCO-DJRRULDNSA-N
2.1.4 Canonical SMILES
CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C(=C(C=C1C)OC)C)C
2.1.5 Isomeric SMILES
CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C
2.2 Other Identifiers
2.2.1 UNII
65M2UDR9AG
2.3 Synonyms
2.3.1 MeSH Synonyms

1. B10 9359

2. B10-9359

3. B109359

4. Ethyl Etrinoate

5. Etrinoate, Ethyl

6. Ro 10 9359

7. Ro 10-9359

8. Ro 109359

9. Ro-10-9359

10. Ro109359

11. Tigason

12. Tigazon

2.3.2 Depositor-Supplied Synonyms

1. 54350-48-0

2. Tegison

3. Ethyl Etrinoate

4. Retinoid

5. Etretinato

6. Ro 10-9359

7. Etretinatum

8. Tigason

9. Ro-109359

10. Chebi:4913

11. Ro-10-9359

12. Ethyl (2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate

13. Nsc-297936

14. 65m2udr9ag

15. Acitretin Related Compound B

16. Ethyl (all-e)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate

17. Ethyl All-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate

18. 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic Acid Ethyl Ester

19. Ncgc00167500-01

20. Dsstox_cid_3036

21. 2,4,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-, Ethyl Ester, (all-e-)

22. Dsstox_rid_76843

23. Dsstox_gsid_23036

24. Etretinatum [inn-latin]

25. Etretinato [inn-spanish]

26. (2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic Acid Ethyl Ester

27. Cas-54350-48-0

28. Ccris 3615

29. Hsdb 7185

30. Sr-05000001511

31. Einecs 259-119-3

32. Unii-65m2udr9ag

33. Nsc 297936

34. Etretinate [usan:inn:ban:jan]

35. 2,4,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, Ethyl Ester, (all-e)-

36. Etretinate [mi]

37. Etretinate [inn]

38. Etretinate [jan]

39. Tegison (tn)

40. Etretinate [hsdb]

41. Etretinate [usan]

42. Etretinate [vandf]

43. Chembl464

44. Etretinate [mart.]

45. Schembl3123

46. Etretinate [who-dd]

47. Etretinate (jan/usan/inn)

48. Gtpl7599

49. Dtxsid0023036

50. Etretinate [orange Book]

51. Chebi:94591

52. 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic Acid Ethyl Ester

53. Hms2090g06

54. Hms3713f22

55. Hy-b0797

56. Zinc3830820

57. Tox21_112501

58. Bdbm50248000

59. Lmpr01090046

60. Mfcd00866624

61. Nsc297936

62. S4699

63. Akos015889992

64. Tox21_112501_1

65. Ac-6823

66. Ccg-220590

67. Cs-3926

68. Ncgc00167500-02

69. Ro-13-7837

70. 2,4,6,8-nonanetetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, Ethyl Ester, All-trans-

71. 2,4,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, Ethyl Ester, (2e,4e,6e,8e)-

72. As-77381

73. Etretinate 100 Microg/ml In Acetonitrile

74. Acitretin Impurity B [ep Impurity]

75. E1293

76. Acitretin Related Compound B [usp-rs]

77. A16356

78. D00316

79. Ab01275503-01

80. 350e480

81. A830117

82. Isopropyl-pyridin-4-yl-aminedihydrochloride

83. Q554297

84. Acitretin Related Compound B [usp Impurity]

85. Sr-05000001511-1

86. Sr-05000001511-2

87. W-105640

88. Brd-k36248164-001-01-8

89. Ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate

90. Ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate

91. (2e,4e,6e,8e)-ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate

92. 2,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, Ethyl Ester, (all E)-

93. 2,6,8-nonatetraenoic Acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, Ethyl Ester, (all-e)-

94. Ethyl (2e,4e,6e,8e)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoate

95. Ethyl (2e,4e,6e,8e)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoate;etretinate

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 354.5 g/mol
Molecular Formula C23H30O3
XLogP36.8
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count8
Exact Mass354.21949481 g/mol
Monoisotopic Mass354.21949481 g/mol
Topological Polar Surface Area35.5 Ų
Heavy Atom Count26
Formal Charge0
Complexity568
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count4
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

Antipsoriatic

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 689


Etretinate is indicated for the treatment of severe recalcitrant psoriasis, including the erythrodermic and generalized pustular types, in patients who are unresponsive to or intolerant of the standard therapies. /Included in US product labeling/

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1330


Etretinate is used for the treatment of severe, intractable oral lichen planus. /NOT included in use product labeling/

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1330


Etretinate is also used in correcting severe intractable forms of keratinization disorders, such as: dermatoses, ichthyosiform; erythroderma, congenital ichthyosiform; ichthyosis, lamellar, and other ichthyoses; keratosis follicularis (Darier's disease); keratosis palmaris et plantaris; pityriasis rubra pilaris (PRP); pustulosis, palmoplanter. /NOT included in US product labeling/

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1330


4.2 Drug Warning

Pregnancy risk category: X /CONTRAINDICATED IN PREGNANCY. Studies in animals or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or risk which clearly outweights any possible benefit to the patient./

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


Etretinate is contraindicated during pregnancy, since it has caused major human fetal abnormalities, including meningomyelocele; meningoencephalocoele; multiple synostoses; facial dysmorphia; syndactyly; absence of terminal phalanges; malformations of hip, ankle, and forearm; abnormalities of the heart and thymus; low set ears; high palate; decreased cranial volume; and alterations of the skull and cervical vertebrae.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


... It has not been determined how long pregnancy should be avoided after discontinuation of treatment; patients have been followed for a long as 2 years after treatment was discontinued, and fetal abnormalities associated with etretinate have occurred during this 2 year period. Therefore, etretinate should not be used in women who plan to have children in the future.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


In women of childbearing potential, etretinate should not be used until the possibility of pregnancy is ruled out. In addition, etretinate should not be used in women who, while undergoing treatment and for an indefinite period of time thereafter, are deemed unreliable in their use of contraception or who may not use reliable contraception.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


For more Drug Warnings (Complete) data for ETRETINATE (13 total), please visit the HSDB record page.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Keratolytic Agents

Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. (See all compounds classified as Keratolytic Agents.)


5.2 ATC Code

D - Dermatologicals

D05 - Antipsoriatics

D05B - Antipsoriatics for systemic use

D05BB - Retinoids for treatment of psoriasis

D05BB01 - Etretinate


5.3 Absorption, Distribution and Excretion

Concentrations of etretinate and its active metabolite in epidermal specimens obtained after 1 to 36 months of therapy were a function of location; subcutis much greater than serum greater than epidermis greater than dermis.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


Etretinate accumulates in high concentrations in adipose tissue, especially in the liver and in subcutaneous fat. Liver concentrations of etretinate in patients who had received therapy for six months were generally higher than accompanying plasma concentrations and tended to be higher still in livers with a higher degree of fatty infiltration.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


Studies in normal volunteers indicate that the absorption of etretinate is greater in patients consuming whole milk or a high-fat diet than in patients in a fasting state.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


Etretinate is absorbed in the small intestine.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


For more Absorption, Distribution and Excretion (Complete) data for ETRETINATE (8 total), please visit the HSDB record page.


5.4 Metabolism/Metabolites

The aromatic retinoid acitretin is the primary active metabolite of etretinate, and in this study the ethyl esterification of acitretin to etretinate using [(14)C]acitretin and human liver microsomes /was investigated/. ... This study demonstrated that in the presence of ethanol the ethyl esterification of acitretin to etretinate proceeds via formation of acitretinoyl-CoA. Predicting clearance of acitretin in vivo via this unique metabolic pathway will be a challenge, as the intracellular concentration of ethanol could never be predicted with any degree of accuracy in humans.

PMID:10874125 Knights KM et al; Biochem Pharmacol 60 (4): 507-16 (2000)


5.5 Biological Half-Life

In one study, the apparent terminal half life of etretinate after 6 months of therapy was approximately 120 days.

Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1331


BUILDING BLOCK

Upload your portfolio for free, ask us

END USE APIs

read-more
read-more
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty